[1]聂明月,叶红*.宫颈病变中人乳头瘤病毒相关微小RNA的研究进展[J].中国计划生育和妇产科,2020,(6):12-15.
点击复制

宫颈病变中人乳头瘤病毒相关微小RNA的研究进展
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2020年6期
页码:
12-15
栏目:
宫颈病变诊治专栏
出版日期:
2020-06-25

文章信息/Info

作者:
聂明月; 叶红*
首都医科大学附属北京妇产医院妇科微创中心
关键词:
人乳头瘤病毒; 宫颈病变; 宫颈癌; 微小RNA
分类号:
R 711.74

参考文献/References:

［1］魏丽惠,谢幸,刘继红，等. 四价人乳头瘤病毒疫苗预防中国大陆女性HPV持续感染及下生殖道相关疾病的保护效力:一项随访78个月的随机对照研究 ［J］.中国妇产科临床杂志,2020,21（2）:158162. ［2］Bedell S L, Goldstein L S, Goldstein A R, et al. Cervical cancer screening: past, present, and future ［J］. Sex Med Rev,2020,8(1):2837. ［3］Santos J, Peixoto D S S, Costa N R, et al. The role of microRNAs in the metastatic process of highrisk HPVinduced cancers ［J］. Cancers (Basel),2018,10(12) :493. ［4］Shukla S, Bharti A C, Mahata S, et al. Infection of human papillomaviruses in cancers of different human organ sites ［J］. Indian J Med Res,2009,130(3):222233. ［5］Gupta S M, ManiaPramanik J. Molecular mechanisms in progression of HPVassociated cervical carcinogenesis ［J］. J Biomed Sci,2019,26(1):28. ［6］Ramos M C, Pizarro D L B, Michelin M A, et al. Highgrade cervical intraepithelial neoplasia, human papillomavirus and factors connected with recurrence following surgical treatment ［J］. Clin Exp Obstet Gynecol,2008,35(4):242247. ［7］Olusola P, Banerjee H N, Philley J V, et al. Human papilloma virusassociated cervical cancer and health disparities ［J］. Cells,2019,8(6) : 622. ［8］Zhu D, Ye M, Zhang W. E6/E7 oncoproteins of high risk HPV16 upregulate MT1MMP, MMP2 and MMP9 and promote the migration of cervical cancer cells ［J］. Int J Clin Exp Pathol,2015,8(5):49814989. ［9］Huh W K, Ault K A, Chelmow D, et al. Use of primary highrisk human papillomavirus testing for cervical cancer screening: interim clinical guidance ［J］. Gynecol Oncol,2015,136(2):178182. ［10］张燕玲，乔志强，李隆玉，等. 宫颈癌及癌前病变患者人乳头瘤病毒感染率的临床分析［J］. 实用癌症杂志,2005，20(2):161163. ［11］张师前，王凯，张远丽. HPV疫苗在中国的应用现状 ［J］. 中国实用妇科与产科杂志,2019,35(10):10901095. ［12］Patel C, Brotherton J M, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?［J］. Euro Surveill,2018,23(41) :1700737. ［13］Palmer T, Wallace L, Pollock K G, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 1213 in Scotland: retrospective population study ［J］. BMJ,2019,365:l1161. ［14］Wang H, Zhang D, Chen Q, et al. Plasma expression of miRNA21, 214, 34a, and 200a in patients with persistent HPV infection and cervical lesions［J］. BMC Cancer,2019,19(1):986. ［15］He Y, Lin J, Ding Y, et al. A systematic study on dysregulated microRNAs in cervical cancer development［J］. Int J Cancer,2016,138(6):13121327. ［16］Zhang L, Liu F, Fu Y, et al. MiR520d5p functions as a tumorsuppressor gene in cervical cancer through targeting PTK2［J］. Life Sci,2020:117558. ［17］Wang F, Liu M, Li X, et al. MiR214 reduces cell survival and enhances cisplatininduced cytotoxicity via downregulation of Bcl2l2 in cervical cancer cells ［J］. FEBS Lett,2013,587(5):488495. ［18］Xu J, Wang H, Wang H, et al. The inhibition of miR126 in cell migration and invasion of cervical cancer through regulating ZEB1［J］. Hereditas,2019,156:11. ［19］Liu S, Pan X, Yang Q, et al. MicroRNA18a enhances the radiosensitivity of cervical cancer cells by promoting radiationinduced apoptosis ［J］. Oncol Rep,2015,33(6):28532862. ［20］Lin F, Wang P, Shen Y, et al. Upregulation of microRNA224 sensitizes human cervical cells SiHa to paclitaxel ［J］. Eur J Gynaecol Oncol,2015,36(4):432436. ［21］Yang Y, Song K L, Chang H, et al. Decreased expression of microRNA126 is associated with poor prognosis in patients with cervical cancer ［J］. Diagn Pathol,2014,9(1):220. ［22］Sammarco M L, Tamburro M, Pulliero A, et al. Human papillomavirus infections, cervical cancer, and micrornas: an overview and implications for public health ［J］. Microrna,2019,9:174. ［23］Snoek B C, Babion I, KoppersLalic D, et al. Altered microRNA processing proteins in HPVinduced cancers ［J］. CurrOpin Virol,2019,39:2332. ［24］Lu H, Qi Z, Lin L, et al. The E6TAp63betaDicer feedback loop involves in miR375 downregulation and epithelialtomesenchymal transition in HRHPV+ cervical cancer cells ［J］. Tumour Biol,2016,37:1580515811. ［25］Sommerova L, Anton M, Bouchalova P, et al. The role of miR4093p in regulation of HPV16/18E6 mRNA in human cervical highgrade squamous intraepithelial lesions ［J］. Antiviral Res,2019,163:185192. ［26］Zhang R, Su J, Xue S L, et al. HPV E6/p53 mediated downregulation of miR34a inhibits Warburg effect through targeting LDHA in cervical cancer ［J］. Am J Cancer Res,2016,6(2):312320. ［27］王红红，郝敏，赵卫红. 微小RNA在宫颈癌中的研究进展 ［J］. 国际妇产科学杂志,2014,41(3):252255. ［28］Satapathy S, Batra J, Jeet V, et al. MicroRNAs in HPV associated cancers: small players with big consequences ［J］. Expert Rev Mol Diagn,2017,17(7):711722. ［29］MelarNew M, Laimins L A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins ［J］.J Virol,2010,84(10):52125221.

相似文献/References:

[1]彭丽霞,张娟.阴道镜下定位活检在宫颈病变诊断中的价值[J].中国计划生育和妇产科,2009,(06):0.
　PENG Li-xia,ZHANG Juan.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(6):0.
[2]陶凤喜,王海新.HPV感染与宫颈病变的关系分析[J].中国计划生育和妇产科,2010,(05):0.
　TAO Feng-xi,WANG Hai-xin.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[3]罗海全,李明,刘兴会,等.宫颈病变锥形切除术后妊娠不良结局相关因素分析[J].中国计划生育和妇产科,2010,(05):0.
　LUO Hai-quan,LI Ming,LIU Xing-hui ..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[4]普俊梅,文勇,黄予,等.高危型HPV DNA检测在宫颈病变筛查和宫颈癌预防中的价值[J].中国计划生育和妇产科,2012,(04):0.
　PU Jun-mei,WEN Yong,HUANG Yu,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[5]帅翰林,罗新.射频消融技术在治疗宫颈病变和宫颈人乳头瘤病毒感染中的作用[J].中国计划生育和妇产科,2013,(01):0.
　SHUAI Han-lin,LUO Xin.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[6]孟跃进,顾晓荔.阴道镜宫颈病变活体组织检查及活体组织检查后治疗问题[J].中国计划生育和妇产科,2013,(01):0.
　MENG Yue-jin,GU Xiao-li.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[7]张宏伟,隋龙.液基细胞学技术在宫颈病变筛查的应用现状及不足[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Hong-wei,SUI Long Medical Center of Diagnostics & Treat for Cervical Disease,Gynaecology and Obstetrics Hospital of Fudan University,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[8]张翼婷,王晓玉,罗新,等.初善仪子宫颈癌筛查系统在宫颈病变筛查中的应用[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Yi-ting,WANG Xiao-yu*,LUO Xin.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[9]陈志龙,史惠蓉.人乳头状瘤病毒L1蛋白在宫颈病变中的表达及其意义[J].中国计划生育和妇产科,2013,(01):0.
　CHEN Zhi-long,SHI Hui-rong*.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[10]钟茜,赵霞.宫颈癌诊治中的过度治疗与治疗不足[J].中国计划生育和妇产科,2013,(02):0.
　ZHONG Xi,ZHAO Xia,[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[11]吴晓菁,谈军,李优云,等.广州市白云区流动人口育龄妇女HPV感染及宫颈病变的流行病学调查[J].中国计划生育和妇产科,2013,(03):0.
　WU Xiao - jing,TAN Jun,LI You - yun,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[12]代鸣,邹志梅,黄江平,等.九江地区9328例宫颈液基细胞学检查结果分析[J].中国计划生育和妇产科,2014,(01):0.
　DAI Ming,ZOU Zhi-mei,HUANG Jiang-ping,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(6):0.
[13]朱木华,林彩菊,叶淑英,等.广东省惠州地区流动人口育龄妇女人乳头瘤病毒感染及宫颈病变的流行病学调查[J].中国计划生育和妇产科,2014,(06):0.
　ZHU Mu-hua,LIN CAI-ju,YE Shu-ying,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(6):0.
[14]钞晓培,谭先杰.人乳头瘤病毒癌基因E6/E7 mRNA检测及其在宫颈病变筛查中的应用价值[J].中国计划生育和妇产科,2016,(10):0.
[15]韩旭,王荣毓*.人乳头瘤病毒与宫颈病变的相关性 及危险因素分析[J].中国计划生育和妇产科,2017,(4):55.
　HAN Xu,WANG Rong-yu*.Correlation between human papillomavirus and cervical lesions andanalysis of risk factors[J].Chinese Journal of Family Planning & Gynecotokology,2017,(6):55.
[16]刘小花*,龙红惠,陈宇宁综述,等.人乳头瘤病毒载量及分型与宫颈病变相关性 研究进展[J].中国计划生育和妇产科,2020,(2):33.

备注/Memo

备注/Memo:
首都医科大学附属北京妇产医院中青年学科骨干培养专项（项目编号：FCYY 201719）
更新日期/Last Update: 2020-06-25